这个短暂的周末,医药创投圈一部分人忙着参与和关注AACR会议,一部分人在疯狂地恶补生物统计学知识。(见:在AACR刷poster和摆摊的人)康方生物披露的依沃西(ivonescimab)临床数据中,总生存期(OS)风险比(HR)为0.777,该结果引发了其美国合作伙伴Summit Therapeutics(SMMT)股价暴跌超36%。以下是事件背景及市场反应的核心原因分析:1. HR值的意义与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.